Phase-3 clinical study for a generic version of GSK's Advair Diskus is complete- Cipla

▴ Phase 3 clinical study for a generic version of GSK s Advair Diskus is complete Cipla
The study completed in the first attempt was conducted over a period of 15 months at over 100 sites enrolling 1,400 asthma patients.

Cipla announced that the phase-3 clinical end-point study for fluticasone propionate and salmeterol inhalation powder(100/50 mcg) has been completed.
Fluticasone propionate and salmeterol inhalation powder 100/50 mcg, 250/50 mcg, 500/50 mcg are generic versions of GSK's Advair Diskus. The product is to be used to treat asthma in patients aged four years and above. In the long term, it will be used to treat chronic obstructive pulmonary disease(COPD), including chronic bronchitis emphysema or both for better breathing and fewer flare-ups.
The phase-3 study was conducted over a period of 15 months at over 100 sites in the US on 1,400 asthma patients. The results showed that the product is therapeutically equivalent to Advair Diskus. Also, there were no safety concerns identified during the trials.
Umang Vohra, MD and Global CEO, Cipla, said, “I am pleased with the successful completion of the phase-three clinical study of generic Advair Diskus. Considering the complexity of clinical endpoint study in the Fluticasone + Salmeterol combination, it is heartening to see that our study was successful in the first attempt. This is an important milestone and is a testament to Cipla’s strong respiratory capabilities, and will go a long way in strengthening our respiratory franchise in the US. Unmatched presence across the care continuum and the widest range of drug-device combinations have established Cipla’s position as a lung leader in India and other key emerging markets. Our endeavor is to extend this expertise across developed markets through niche product development.”

Tags : #Advaitdiskus #Cipla #Clinicaltrial #GSK #UmnagVohra #Asthmapatients

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025